Sofgen Pharma S.A.
PROCF
Other OTC0.03
USD
- -
- -
ISIN
LU2376511205
CUSIP
237649125
Return %
Stock
S&P500
1Y
-98.21
18.86
3Y
-99.37
64.57
5Y
-99.74
71.65
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Melissa Angelini
- Full Time Employees
- 5,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 9 Rue de Bitbourg Luxembourg City LU Luxembourg 1273
- IPO Date
- Oct 4, 2021
- Website
- procapsgroup.com
- Similar Companies
- Business
- Procaps Group S.A. engages in the development, manufacture, and global distribution of pharmaceutical and nutraceutical products, with a focus on advanced delivery technologies and contract development and manufacturing services. The company operates through Softgel and capsule platforms, prescription medicines, over-the-counter products, diabetes management solutions, and nutraceuticals, serving healthcare systems, hospitals, pharmacies, and private-label channels across multiple regions. Headquarters are in Luxembourg, and the group maintains substantial operations in North, Central, and South America, including production facilities and regional subsidiaries aimed at responding to diverse therapeutic areas and consumer health needs. Main products and services - Softgel and capsule technologies: contract development and manufacturing of soft gelatin capsules for prescription drugs, nutraceuticals, and specialty therapies; proprietary platforms such as Softgel, Sofgen, and Softcaps brands; formulation development, process optimization, scale-up, and quality assurance. - Solid oral dosage forms: tablets and capsules produced for various therapeutic areas, with capabilities in complex formulations and controlled-release technologies. - Prescription pharmaceuticals: development, manufacture, and commercialization of high-complexity medicines across cardiovascular, central nervous system, gastrointestinal, respiratory, oncology, and other therapeutic areas. - Over-the-counter medicines and consumer health: broad portfolio of cough and cold, analgesics, gastrointestinal, dermatological, vitamins, minerals, and dietary supplements, distributed through regional networks. - Diabetes solutions: blood glucose monitoring devices, oral antidiabetics, insulin delivery systems, and related diabetes management tools under the Diabetrics umbrella. - Nutraceuticals and functional foods: customized health and wellness products, including gummies and other specialty formats, produced to meet regulatory and quality standards. - Contract development and manufacturing services (CDMO): full-service outsourcing for third-party pharmaceutical and nutraceutical companies, emphasizing softgel technologies, scalability, regulatory compliance, and quality systems. - Product development and regulatory support: formulation development, stability studies, quality assurance, regulatory affairs, and technical documentation to support market approvals and lifecycle management. - Hospital and clinical supply: medicines and medical supplies designed for hospital use, chronic disease management, and patient care pathways. - Global distribution and regional commercialization: international supply chains, warehousing, logistics, and market access support across the Americas and other regions. Latest major company changes - Strategic partnerships and alliances: forms collaborations with global pharma and nutraceutical players to expand CDMO capacity, accelerate product development, and broaden market reach across North and South America. - Funding and capital actions: executes financing and potential capital-raising activities to support expansion of manufacturing footprint and technology platforms, including investments in advanced delivery systems and capacity upgrades. - Product and service launches: introduces new softgel and gummy delivery platforms, expands Diabetrics diabetes management portfolio, and broadens over-the-counter and hospital products to address emerging therapeutic needs. - Expansion and restructuring: scales manufacturing capabilities with multi-site capacity expansion in the Americas; enhances regulatory and quality systems to support faster time-to-market for new products. - Corporate structure: maintains an international footprint with subsidiaries and regional entities; reinforces governance and cross-border operations to optimize global sourcing, manufacturing, and distribution networks. Industry context and business segments - Industry: pharmaceutical and nutraceutical development, manufacturing, and distribution; contract development and manufacturing (CDMO) services; consumer health and wellness products. - Segments: Softgel advanced technologies (core CDMO operations), solid oral dosage forms, prescription medicines, over-the-counter and consumer health products, diabetes solutions, nutraceuticals, and hospital supplies. - Customers: pharmaceutical companies, biotechnology firms, healthcare providers, hospitals, pharmacies, and distributors requiring scale, regulatory compliance, and specialized delivery technologies. - Geographic operations: multinational presence across the Americas with manufacturing facilities and sales offices in North, Central, and South America; head office in Luxembourg with related corporate functions in Europe and the Americas. - Founding year and headquarters: founded in 1977; headquarters listed in Luxembourg, with operational hubs across Colombia, the United States, Brazil, and other countries in the Americas. - Subsidiaries and structure: operates under branded platforms and regional units such as Softigel, Sofgen, Softcaps, Funtrition, and other CDMO and consumer health brands, with a corporate structure supporting cross-border development, manufacturing, and distribution.
Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership